SLCO1B3 and prostate carcinoma: OATP1B3-mediated testosterone uptake is greater in cells expressing certain OATP1B3 variants (112S and 233M), and these variants are also associated with poor overall survival from diagnosis, poor progression-free survival on androgen deprivation therapy, biochemical recurrence, and prostate cancer-specific mortality6,7,9,10.